(S)-5-(2-allylphenoxymethyl)-1,3-oxazolidin-2-one | 852805-34-6

• 英文名称: (S)-5-(2-allylphenoxymethyl)-1,3-oxazolidin-2-one
• CAS: 852805-34-6
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: JVLBANGZEUEIEB-NSHDSACASA-N

物化性质

• 沸点：
  439.4±14.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  47.56
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (S)-5-(2-allylphenoxymethyl)-1,3-oxazolidin-2-one 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 乙醇 、 水 为溶剂， 生成 2-丙醇,1-[(1-甲基乙基)氨基]-3-[2-(2-丙烯-1-基)苯氧基]-,(2S)-
  参考文献：
  名称：

  New chemoenzymatic pathway for β-adrenergic blocking agents

  摘要：

  The lipase mediated kinetic resolution of pharmaceutically important beta-hydroxy nitrites is described in high enantionteric excesses and good yields. Some of the chiral beta-hydroxy nitriles have been employed in the synthesis of P-adrenergic blocking agents such as propranolol, alprenolol and moprolol. This protocol has also been extended for the enantiopure preparation of 5-(4-tosyloxymethyl)-1,3-oxazolidine-2-one and 3-liydroxy-4-tosyloxybutaiieiiitrile, chiral intermediates of high synthetic value. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.02.015
• 作为产物：
  描述：

  (S)-4-(2-allylphenoxy)-3-hydroxybutanamide 在 吡啶 、 lead(IV) acetate 作用下， 生成 (S)-5-(2-allylphenoxymethyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  New chemoenzymatic pathway for β-adrenergic blocking agents

  摘要：

  The lipase mediated kinetic resolution of pharmaceutically important beta-hydroxy nitrites is described in high enantionteric excesses and good yields. Some of the chiral beta-hydroxy nitriles have been employed in the synthesis of P-adrenergic blocking agents such as propranolol, alprenolol and moprolol. This protocol has also been extended for the enantiopure preparation of 5-(4-tosyloxymethyl)-1,3-oxazolidine-2-one and 3-liydroxy-4-tosyloxybutaiieiiitrile, chiral intermediates of high synthetic value. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.02.015